#None #GLP-1 #weight loss #Calibrate

Introduction

Calibrate has recently published its 2026 Results Report, a comprehensive analysis of its integrated clinical and coaching solution for obesity care. The report is based on extensive data, with more than 50,000 members contributing to a remarkable longitudinal study that spans close to six years of clinical insights.

Key Findings

The findings illustrate a consistent trend in weight loss among Calibrate members using GLP-1 medications, showing an average weight loss of 16% within the first year. The results continue to improve, with 18% after the second year, 20% in the third, and escalating to an impressive 21% by the fourth year. This continuous trend, especially among higher-risk populations, highlights a significant breakthrough in obesity management.

Impacts on High-Risk Members

Among those starting from Class II and Class III Obesity—the groups most at risk and most costly for employers—the analysis indicates profound weight loss of 17% and 16% respectively in year one. This further progresses to 23% and 27% by the fourth year, demonstrating that Calibrate’s approach effectively nurtures long-term health improvements.

Health Benefits Beyond Weight Loss

Notably, the program does not merely focus on weight reduction. Within just one year, a staggering 80% of participants presenting with diabetes or prediabetes normalized their HbA1c levels. Other significant improvements were also documented, such as 72% returning to normal insulin levels and nearly 50% normalizing C-reactive protein levels, essential indicators of metabolic health.

Recovery of Value from Past Users

The analysis also sheds light on the potential for recovering value from past GLP-1 users. Previous users engaging with Calibrate's program witnessed a notable 12% weight loss within the first year, leveraging what could have otherwise been deemed a sunk cost.

Diverse Workforce Impacts

The results hold across different demographics and industries—from high-stress environments in tech and finance to physically demanding roles in manufacturing. This broad applicability underscores the program’s versatility and ability to resonate with varying employee backgrounds.

Role of Coaching and Accountability

A highlight of the study is the emphasis on ongoing support. Members who actively attended coaching sessions saw a 16% greater weight loss compared to those who minimally participated. similarly, tracking food intake, sleep patterns, and energy levels significantly boosted weight loss, showcasing the power of active participation in achieving health goals.

Conclusion

Dr. Linda Anegawa, Calibrate's Chief Medical Officer, emphasizes the holistic nature of this approach. The combination of medication with tailored support forms the core of effective obesity management, ensuring not just short-term results but meaningful, long-lasting health improvements. Employers looking to invest in employee health may find compelling evidence here, as the benefits extend beyond individual health to substantial economic value for organizations overall.

Future Implications

Calibrate, being a pioneer in this digital transformation within obesity management, sets a precedent with its data-driven insights. With ongoing partnerships across various industries, the hope remains that these findings encourage broader acceptance and implementation of collaborative health programs. As Calibrate aims to continue innovating within this space, the potential for improved outcomes in workforce wellness and reduced healthcare costs remains significant.

To access the full report 'Maximizing the Clinical and Economic Value of GLP-1 Therapy', please visit Calibrate's official website.